IVX: IVAX Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVX: IVAX Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (49)	4/28/2004 12:48:40 PM
From: Jim Oravetz	Read Replies (1) of 78

Generic Drug Firms to Meet, Beat 1st-Quarter Estimates By HOLLISTER H. HOVEY DOW JONES NEWSWIRES April 27, 2004 6:02 p.m. ..Ivax Corp., which reports on Thursday, should be able to "handily" beat Lehman Brothers analyst Richard Silver's low-end estimate of 15 cents a share, he said. The average Wall Street estimate calls for the company to earn 18 cents a share, which implies 20% growth from the 15 cents a share the company earned last year. Mr. Silver expects Ivax's revenue to rise 40% to $422 million. Sales should be boosted by modest growth of the generic version of Glaxo's antibiotic Augmentin as well as asthma drug Q-Var and generic Glucophage, a diabetes drug originally marketed by Merck & Co..... Lehman makes a market in the shares of Watson, Barr, Mylan and Ivax.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next